Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000409386 | SCV000486716 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2016-07-22 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001861390 | SCV002130711 | pathogenic | Spastic paraplegia | 2021-05-17 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the SACS protein. Other variant(s) that disrupt this region (p.Tyr4538*) have been determined to be pathogenic (Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with SACS-related conditions. The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the ExAC database. This sequence change creates a premature translational stop signal (p.Ser2874Trpfs*9) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 1706 amino acid(s) of the SACS protein. |
Mendelics | RCV000409386 | SCV002518998 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-05-04 | criteria provided, single submitter | clinical testing |